Literature DB >> 26286367

Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.

Javier Valero-Elizondo1, Yuhree Kim1, Jason D Prescott1, Georgios A Margonis1, Thuy B Tran2, Lauren M Postlewait3, Shishir K Maithel3, Tracy S Wang4, Jason A Glenn4, Ioannis Hatzaras5, Rivfka Shenoy5, John E Phay6, Kara Keplinger6, Ryan C Fields7, Linda X Jin7, Sharon M Weber8, Ahmed Salem8, Jason K Sicklick9, Shady Gad9, Adam C Yopp10, John C Mansour10, Quan-Yang Duh11, Natalie Seiser11, Carmen C Solorzano12, Colleen M Kiernan12, Konstantinos I Votanopoulos13, Edward A Levine13, George A Poultsides2, Timothy M Pawlik14,15.   

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis. Given the lack of data on readmission after resection of ACC, the objective of the current study was to define the incidence of readmission, as well as identify risk factors associated with readmission among patients with ACC who underwent surgical resection.
METHODS: Two hundred nine patients who underwent resection of ACC between January 1993 and December 2014 at 1 of 13 major centers in the USA were identified. Demographic and clinicopathological data were collected and analyzed relative to readmission.
RESULTS: Median patient age was 52 years, and 62 % of the patients were female. Median tumor size was 12 cm, and the majority of patients had an American Society of Anesthesiologists (ASA) class of 3-4 (n = 85, 56 %). The overall incidence of readmission within 90 days from surgery was 18 % (n = 38). Factors associated with readmission included high ASA class (odds ratio (OR), 4.88 (95 % confidence interval (CI), 1.75-13.61); P = 0.002), metastatic disease on presentation (OR, 2.98 (95 % CI, 1.37-6.46); P = 0.006), EBL (>700 mL: OR, 2.75 (95 % CI, 1.16-6.51); P = 0.02), complication (OR, 1.91 (95 % CI, 1.20-3.05); P = 0.007), and prolonged length of stay (LOS; ≥9 days: OR, 4.12 (95 % CI, 1.88-9.01); P < 0.001). On multivariate logistic regression, a high ASA class (OR, 4.01 (95 % CI, 1.44-11.17); P = 0.008) and metastatic disease on presentation (OR, 3.44 (95 % CI, 1.34-8.84); P = 0.01) remained independently associated with higher odds of readmission.
CONCLUSION: Readmission following surgery for ACC was common as one in five patients experienced a readmission. Patients with a high ASA class and metastatic disease on presentation were over four and three times more likely to be readmitted after surgical treatment for ACC, respectively.

Entities:  

Keywords:  Adrenocortical carcinoma; Readmission; Surgery

Mesh:

Year:  2015        PMID: 26286367      PMCID: PMC4951184          DOI: 10.1007/s11605-015-2917-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  37 in total

Review 1.  Current and emerging therapies for adrenocortical carcinoma--review.

Authors:  Justyna Przytulska; Natalia Rogala; Grażyna Bednarek-Tupikowska
Journal:  Adv Clin Exp Med       Date:  2015 Mar-Apr       Impact factor: 1.727

2.  Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Shelby Reed; Randall Scheri; Sanziana Roman; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-07-29       Impact factor: 5.344

3.  Risk factors for 30-day hospital readmission after thyroidectomy and parathyroidectomy in the United States: An analysis of National Surgical Quality Improvement Program outcomes.

Authors:  Matthew G Mullen; Damien J LaPar; Sara K Daniel; Florence E Turrentine; John B Hanks; Philip W Smith
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

4.  Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.

Authors:  Tarek Ezzat Abdel-Aziz; Parameswaran Rajeev; Greg Sadler; Andrew Weaver; Radu Mihai
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

5.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

6.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

7.  Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach.

Authors:  Gianluca Donatini; Robert Caiazzo; Christine Do Cao; Sebastien Aubert; Carlos Zerrweck; Ziad El-Kathib; Thomas Gauthier; Emmanuelle Leteurtre; Jean-Louis Wemeau; Marie Christine Vantyghem; Bruno Carnaille; Francois Pattou
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

8.  Readmissions after major urologic cancer surgery.

Authors:  Jeffrey J Leow; Giorgio Gandaglia; Akshay Sood; Nedim Ruhotina; Dane E Klett; Jesse D Sammon; Marianne Schmid; Maxine Sun; Steven L Chang; Adam S Kibel; Quoc-Dien Trinh
Journal:  Can J Urol       Date:  2014-12       Impact factor: 1.344

9.  Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies.

Authors:  Eric B Schneider; Omar Hyder; Christopher L Wolfgang; Kenzo Hirose; Michael A Choti; Martin A Makary; Joseph M Herman; John L Cameron; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

Review 10.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.